Quadrivalent Recombinant Seasonal Influenza Vaccine

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

InfluenzaInfluenza Immunisation

Phase 1

Flublok or Fluzone With Advax-CpG55.2 or AF03

CompletedNCT03945825

National Institute of Allergy and Infectious Diseases (NIAID)Influenza, Influenza Immunisation

Start: 2019-06-10End: 2020-09-18Updated: 2025-10-14

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Active, not recruitingNCT05945485

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2023-10-16End: 2026-06-01Updated: 2026-03-20

Phase 2

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

CompletedNCT03058692

National Institute of Allergy and Infectious Diseases (NIAID)Influenza, Influenza Immunisation

Start: 2018-04-09End: 2019-01-14Updated: 2020-06-18

Related Papers

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.

2025-03-182 citations

Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.

2023-03-2113 citations